Ipsen SA · EURONEXT:IPN
Ipsen SA — JP Morgan 33rd Annual Healthcare Conference (January 2015)
27 slides from Ipsen SA's conference presentation, January 2015
Slide 1: Ipsen – JP Morgan 33rd Annual Healthcare Conference
Ipsen JP Morgan 33rd Annual Healthcare Conference Marc de Garidel – Chairman and CEO
Slide 2: Disclaimer
Disclaimer This presentation includes only summary information and does not purport to be comprehensive. Forward-looking statements, targets and estimates contained herein are for illustrative purposes only and are based on management’s current views and assumptions. Such statements involve known an
Slide 3: Safe Harbor
Safe Harbor The Group operates in certain geographical regions whose governmental finances, local currencies or inflation rates could be affected by the current crisis, which could in turn erode the local competitiveness of the Group’s products relative to competitors operating in local currency, an
Slide 4: Agenda
Agenda 1 Strategy update 2 Organic growth levers 3 Business development initiatives 4 2014 key achievements 4 Ipsen – JP Morgan 33rd Annual Healthcare Conference 4 Goldman Sachs 35th Annual Global Healthcare Conference – June 2014
Slide 5: Strategy update
Strategy update
Slide 6: Ipsen to become a global leader in targeted debilitating diseases
Ipsen to become a global leader in targeted debilitating diseases Increase Focus Invest to Grow Leverage Footprint Transform the company Lean organization Process simplification Cost control 2020 ambition (1) More than double revenues… …and more than triple Core Operating Income 6 Ipsen – JP Morgan
Slide 7: Ipsen has become a specialty pharma with a global footprint
Ipsen has become a specialty pharma with a global footprint 9m 2014 sales by segment 9m 2014 sales by geography Primary care ~25% Emerging Europe G5 39% 40% markets ~75% Specialty care 6% 14% US Developed RoW US and emerging markets to support future growth Increasing weight of Specialty care 7 Ipse
Slide 8: Key achievements 2011-2014
Key achievements 2011-2014 Solid specialty care growth / end of primary care erosion Acceleration of FDA approval of Somatuline® in GEP NET(1) sales growth Preparation for US launch Pipeline progression with Dysport® in spasticity and tasquinimod in prostate cancer Increased operational focus with a
Slide 9: Focus strategy and transformation driving profitability improvement
Focus strategy and transformation driving profitability improvement while preparing for Somatuline® & Tasq launches (1) Evolution of Ipsen’s core operating margin ~20.0% 18,5% 18,6% (2) (2) 2012 2013 Guidance 2014 Ipsen to continue delivering profitable growth (1) Key management indicator, notably i
Slide 10: Organic growth drivers
Organic growth drivers
Slide 11: Six new pipeline products/indications to potentially hit market in sequence
Six new pipeline products/indications to potentially hit market in sequence Addressable market(1) Somatuline® WW NET launch 2015 ~€1B Dysport® US AUL launch Dysport® US ALL launch 2016 ~€100M Dysport® US PLL launch TasQ European launch 2017/2018 [€1.3B-€1.5B] Telotristat European launch (1) Ipsen es
Slide 12: Somatuline, the first and only antitumoral SSA approved in the US for GEP-NETs
Somatuline®, the first and only antitumoral SSA approved in the US for the treatment of GEP-NETs Expansion potential for Somatuline® Somatuline® Aggressive therapies Watch & Wait Competitors Aggressive therapies + SSA Somatuline®, first agent demonstrating a statistically significant PFS benefit in
Slide 13: Somatuline, a best in class product
Somatuline®, a best in class product Increased extended dosing interval worldwide(1) New device Approved in the US in March 2011 Improved Technology with retractable needle From one injection every 4 weeks (all forms) to every Enhanced, prefilled and ready-to-use, low-volume 6-8 weeks (120mg
Slide 14: US platform ready for commercial launch of Somatuline in GEP NET
US platform ready for commercial launch of Somatuline® in gastrointestinal and pancreatic NET H1 2014 H2 2014 H1 2015 Q1 Q2 Q3 Q4 Q1 Q2 Go-it alone decision in the US Cynthia Schwalm & full Cynthia Schwalm appointed US executive team hired for launch President & CEO of IPSEN N.A. Regulatory/ C
Slide 15: Ipsen well-positioned to become a leader in neurotoxins
Ipsen well-positioned to become a leader in neurotoxins 1 AUL(1) spasticity filed in the US Expand US market PLL(2) and ALL(3) spasticity Phase III topline results expected Q1 2015 opportunity Positive Phase II results in NDO(4) Ipsen’s liquid toxin (Dysport® Next Generation) : 2 – Phase III
Slide 16: Ipsen to benefit from aesthetics market growth through its partnership with Galderma
Ipsen to benefit from aesthetics market growth through its partnership with Galderma ~€1bn global toxin aesthetics market(1) 1 High growth and profitable market ~50% US Reinforced alliance with Galderma, 2 a global leader in aesthetics and dermatology ~ 50% ROW Territories covered by the partnership
Slide 17: Decapeptyl to benefit from life-cycle management and emerging market growth
Decapeptyl® to benefit from life-cycle management and emerging market growth… Backbone therapy 3-month subcutaneous 1 for prostate cancer care 2 route of administration LHRH to be used in combination (new hormones, Enlarged patient pool (in particular patients with chemotherapy) anti-coagulant)
Slide 18: Tasquinimod, the first oral immunotherapy targeting the tumor micro-environment in mCRPC
TasQuinimod, the first and unique oral immunotherapy targeting the tumor micro-environment in mCRPC A unique mechanism TasQuinimod is a first-in-class oral immunotherapy of action… targeting the Tumor Micro-Environment … which could fill gaps in the Some patients do not respond to/ escape curren
Slide 19: Business development
Business development
Slide 20: Partnerships at the heart of Ipsen's innovation
Partnerships at the heart of Ipsen’s innovation Endocrinology Neurology Oncology 20 Ipsen – JP Morgan 33rd Annual Healthcare Conference 20 Goldman Sachs 35th Annual Global Healthcare Conference – June 2014
Slide 21: Continued business development efforts to complement organic growth
Continued business development efforts to complement organic growth Areas of focus In-licensing or acquisition of marketed drugs (including orphan drugs) Commercial deals Acquisition of small companies Various geographies targeted, notably the US Late stage compounds (Phase III) in various t
Slide 22: Bolt-on acquisitions and in-licensing: example of Lexicon's telotristat etiprate
Bolt-on acquisitions and in-licensing to leverage existing platforms: example of Lexicon’s telotristat etiprate Agreement Carcinoid syndrome treatment Telotristat etiprate (LX1032) is a late phIII compound for treatment of symptomatic NETs in patients whose carcinoid syndrome is not SSA adequately
Slide 23: 2014 key achievements
2014 key achievements
Slide 24: Strong base business fueled by specialty care
Strong base business fueled by specialty care Drug sales – 9M 2014 in million euros – % excluding foreign exchange impact ® Decapeptyl +10.2% 243.4 ® Specialty care Specialty care Somatuline +15.5% 213.6 €718.2m ® Dysport +8.8% 195.3 +10.4% ® Nutropin +6.7% 45.1 ® Hexvix 12.1 +12.9% Group sales ® €9
Slide 25: 2014 financial objectives
2014 financial objectives Specialty care – Drug sales Growth of +9.0% to +10.0%, year-on-year Primary care – Drug sales Growth of -1.0% to 1.0%, year-on-year Core operating margin Around 20.0% of sales – Resulting from sales performance and cost containment initiatives, notably French Primary Care a
Slide 26: Key takeaways
Key takeaways Focus strategy is delivering 1 Strong base business growth and cost control Significant Somatuline® NET opportunity 2 with strong US label Pipeline catalysts with Dysport® spasticity and 3 tasquinimod in prostate cancer Continued business development efforts to complement 4 organic gro
Slide 27: Thank you
Thank you
Ipsen — JP Morgan 33rd Annual Healthcare Conference (January 2015) on 6ix